Antidepressant-Associated Weight Loss

Primary Recommendation: Bupropion

Bupropion is the primary antidepressant with consistent weight loss properties, demonstrating a pooled weight loss of 2.77 kg at 6-12 months when used as monotherapy, and is the only antidepressant shown to consistently promote weight loss rather than weight gain or weight neutrality, according to the American College of Physicians 1, 2
Bupropion should be the first-line antidepressant choice when weight loss is a treatment priority, as it is the only agent in its class with documented weight-reducing effects across multiple formulations and indications, as recommended by the American Gastroenterological Association 3

Monotherapy for depression: Bupropion produces a mean weight loss of 2.77 kg over 6-12 months in patients with major depressive disorder, with a moderate strength of evidence, according to the American College of Physicians 1, 2
FDA-approved combination therapy: Naltrexone/bupropion extended-release is FDA-approved specifically for obesity treatment, demonstrating 6.1% weight loss versus 1.3% with placebo at 56 weeks, with 48% of patients achieving ≥5% weight loss, with a high strength of evidence, according to the American Gastroenterological Association 4, 5, 6

Bupropion functions as a dopamine and norepinephrine reuptake inhibitor, modulating central reward pathways triggered by food and suppressing appetite while reducing food cravings, with a moderate strength of evidence, according to the American Gastroenterological Association 4, 6, 3

Bupropion is particularly appropriate for patients with concomitant depression requiring treatment, with a moderate strength of evidence, according to the American Gastroenterological Association 6
Bupropion is also suitable for patients with a desire to quit smoking, with a high strength of evidence, according to the American Gastroenterological Association 6, 3

Avoid bupropion in patients with uncontrolled hypertension, with a high strength of evidence, according to the American Gastroenterological Association 6
Avoid bupropion in patients with a history of seizures or conditions predisposing to seizures, with a high strength of evidence, according to the American Gastroenterological Association 6

Fluoxetine at 60 mg daily demonstrates weight loss of 4.74 kg at 6 months and 3.15 kg at 12 months, with a low strength of evidence, according to the American College of Physicians 1, 7, 2

If bupropion is contraindicated, sertraline and fluoxetine at standard antidepressant doses (20 mg) are weight-neutral with long-term use, making them preferable to weight-gaining alternatives, with a moderate strength of evidence, according to the American Gastroenterological Association 3

Do not use sertraline expecting weight loss, despite one small study, with a low strength of evidence, according to the American College of Physicians 1, 7
Do not prescribe paroxetine or mirtazapine, as they are associated with the greatest weight gain risk within their respective classes, with a high strength of evidence, according to the American Gastroenterological Association 3